Balyasny Asset Management LLC Inozyme Pharma, Inc. Transaction History
Balyasny Asset Management LLC
- $54.8 Billion
- Q1 2024
A detailed history of Balyasny Asset Management LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 31,380 shares of INZY stock, worth $167,255. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,380Holding current value
$167,255% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
92Shares Held
49MCall Options Held
1.6KPut Options Held
22K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.33MShares$28.4 Million0.08% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$24 Million25.25% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$22.8 Million1.91% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.68MShares$19.6 Million0.74% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.18MShares$16.9 Million0.39% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $214M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...